Pamidronate for the treatment of osteoporosis secondary to chronic cholestatic liver disease in Wistar rats

about

Hepatic Osteodystrophy: The Mechanism of Bone Loss in Hepatocellular Disease and the Effects of Pamidronate Treatment.

P2860

Q33592706-A6898197-BEC6-4029-9649-F2F9891D761D

P2860

Pamidronate for the treatment of osteoporosis secondary to chronic cholestatic liver disease in Wistar rats

Item

http://www.wikidata.org/entity/Q37370997

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 September 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pamidronate for the treatment ...... c liver disease in Wistar rats

@en

Pamidronate for the treatment ...... liver disease in Wistar rats.

@nl

type

Item

label

Pamidronate for the treatment ...... c liver disease in Wistar rats

@en

Pamidronate for the treatment ...... liver disease in Wistar rats.

@nl

prefLabel

Pamidronate for the treatment ...... c liver disease in Wistar rats

@en

Pamidronate for the treatment ...... liver disease in Wistar rats.

@nl

P1476

Pamidronate for the treatment ...... c liver disease in Wistar rats

@en

P2093

F A Pereira

http://www.w3.org/2001/XMLSchema#string

F J A de Paula

http://www.w3.org/2001/XMLSchema#string

H L A Defino

http://www.w3.org/2001/XMLSchema#string

I Facincani

http://www.w3.org/2001/XMLSchema#string

J B Volpon

http://www.w3.org/2001/XMLSchema#string

L N Z Ramalho

http://www.w3.org/2001/XMLSchema#string

R Mattar

http://www.w3.org/2001/XMLSchema#string

V Jorgetti

http://www.w3.org/2001/XMLSchema#string

P2860

Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee

A systematic review of the effectiveness of strategies for reducing fracture risk in children with juvenile idiopathic arthritis with additional data on long-term risk of fracture and cost of disease management.

Hepatic osteodystrophy and liver cirrhosis.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Targeted and nontargeted remodeling.

The role of GH/IGF-I-mediated mechanisms in sex differences in cortical bone size in mice

Serum IGF-1 affects skeletal acquisition in a temporal and compartment-specific manner.

Elevated serum levels of IGF-1 are sufficient to establish normal body size and skeletal properties even in the absence of tissue IGF-1.

Hepatic osteodystrophy: An important matter for consideration in chronic liver disease.

P304

1255-1261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1590/S0100-879X2012007500143

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230863928

http://www.w3.org/2001/XMLSchema#string

P698

22983176

http://www.w3.org/2001/XMLSchema#string

P921

osteoporosis

P932

3854229

http://www.w3.org/2001/XMLSchema#string

Pamidronate for the treatment of osteoporosis secondary to chronic cholestatic liver disease in Wistar rats

about

P2860

P2860

Pamidronate for the treatment of osteoporosis secondary to chronic cholestatic liver disease in Wistar rats

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932